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Recently, the highly mutated oncoprotein K-Ras4B (hereafter K-Ras) was shown to drive
cancer cell stemness in conjunction with calmodulin (CaM). We previously showed that
the covalent CaM inhibitor ophiobolin A (OphA) can potently inhibit K-Ras stemness
activity. However, OphA, a fungus-derived natural product, exhibits an unspecific,
broad toxicity across all phyla. Here we identified a less toxic, functional analog of
OphA that can efficiently inactivate CaM by covalent inhibition. We analyzed a small
series of benzazulenones, which bear some structural similarity to OphA and can be
synthesized in only six steps. We identified the formyl aminobenzazulenone 1, here
named Calmirasone1, as a novel and potent covalent CaM inhibitor. Calmirasone1 has a
4-fold increased affinity for CaM as compared to OphA and was active against K-Ras in
cells within minutes, as compared to hours required by OphA. Calmirasone1 displayed
a 2.5–4.5-fold higher selectivity for KRAS over BRAF mutant 3D spheroid growth than
OphA, suggesting improved relative on-target activity. Importantly, Calmirasone1 has
a 40–260-fold lower unspecific toxic effect on HRAS mutant cells, while it reaches
almost 50% of the activity of novel K-RasG12C specific inhibitors in 3D spheroid assays.
Our results suggest that Calmirasone1 can serve as a new tool compound to further
investigate the cancer cell biology of the K-Ras and CaM associated stemness activities.
Keywords: K-Ras, calmodulin, covalent inhibitor, cancer stem cell (CSC), BRET
INTRODUCTION
Calmodulin (CaM) is a small (17 kDa) dumbbell-shaped signaling adapter, with hundreds of
protein interactions and widespread functions in cellular signaling (Tidow and Nissen, 2013). Its
two N- and C-terminal lobes each contain two EF-hands that can coordinate altogether four Ca2+
ions. Ca2+/CaM classically recognizes with high, nanomolar affinity approximately 20-residue
long peptides with bulky hydrophobic and basic residues that become encased in the hydrophobic
pocket formed by the two lobes. This leads to a significant conformational change of CaM with loss
of the central helical structure (Tidow and Nissen, 2013). Non-canonical CaM binders typically
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possess a polybasic N- or C-terminus with a single lipid
modification, which can bind to either or both of the hydrophobic
pockets on the N- and C-lobes (Grant et al., 2020b).
CaM has been pursued as a cancer drug target in the
1980s due to its significant role in activating CDKs in the
cell cycle (Hait and Lazo, 1986). CaM levels increase during
the cell cycle, peaking at G2/M, with a drop-off thereafter
(Berchtold and Villalobo, 2014). In addition, CaM seems
to be indirectly important for the activation of CDKs that
are active in G1 (Taules et al., 1998). CaM distribution is
furthermore tightly associated with cell division, as it co-
distributes with major structures of the mitotic machinery, such
as the central spindle, centrosomes, and the cleavage furrow
(Li et al., 1999; Yu et al., 2004). In line with this, CaM
inhibitors have been demonstrated to block tumor growth,
such as, for example, in multiple myeloma cell line xenografts
(Yokokura et al., 2014).
Several non-covalent CaM inhibitors have been developed
including the frequently used calmidazolium (Sunagawa
et al., 1999) and the highly water-soluble and cell-penetrating
naphthalenesulfonamides, such as W-7 (Hidaka et al., 1981;
Sengupta et al., 2007). However, the latter can also inhibit
CaM targets, such as Ca2+/CaM-dependent cyclic nucleotide
phosphodiesterase at concentrations > 100 µM (Itoh and
Hidaka, 1984; Zimmer and Hofmann, 1984).
Ophiobolin A (OphA) is a potent, covalent CaM inhibitor
(Leung et al., 1984). It is a naturally occurring fungal 5-8-
5 tricyclic sesterterpene metabolite with broad toxicity against
plants, microbes, and cancer cells (Au et al., 2000). It
forms an irreversible covalent adduct via C5, C21-dicarbonyl
functionalities after intermediate Schiff base formation with Lys
75 or Lys 77 and Lys 148 of CaM (Supplementary Scheme
1). Thus, OphA can react with CaM at a 2:1 ratio, similar to
covalent phenothiazine derivatives, which also react with the
same lysines (Faust et al., 1987). Despite its potency against
CaM, OphA appears to have several other targets, such as
phosphatidylethanolamine (Chidley et al., 2016). Together with
its broad toxicity across most phyla, this suggests a problematic
toxicity spectrum of OphA.
We previously identified OphA as a K-Ras4B (hereafter
K-Ras) but not an H-Ras selective inhibitor (Najumudeen et al.,
2016). OphA disrupts membrane organization of K-Ras in a
CaM-dependent manner and blocked the growth of cancer
stem cell enriched spheroids derived from breast cancer cell
lines. Up to two K-Ras proteins can directly bind to the two
lobes of Ca2+/CaM (Agamasu et al., 2019; Grant et al., 2020a).
Interestingly, K-Ras has a higher affinity to the C-terminal
lobe (KD = 0.5 µM) than to the N-terminal lobe (KD = 4
µM). Complementary to this, the C-terminal lobe of CaM
binds Ca2+ with higher affinity compared to the N-terminal
lobe (Teleman et al., 1986). This affinity constellation may
underpin a Ca2+-mediated K-Ras release mechanism. Binding
of K-Ras is nucleotide-independent but dependent on the
farnesylated C-terminus, while also geranylgeranylation mediates
binding albeit with an almost 10-fold lower affinity (Wu
et al., 2011; Agamasu et al., 2019; Grant et al., 2020a). In
addition, basic residues of the hypervariable region of K-Ras
may contribute to the interaction; however, interaction with
the prenyl moiety provides the core affinity (Jang et al.,
2019; Grant et al., 2020a). In contrast to these more recently
established binding determinants, a preference of CaM binding
to GTP-K-Ras was previously observed (Villalonga et al., 2001;
Abraham et al., 2009).
Experimental data show that palmitoylated Ras isoforms do
not interact with CaM (Villalonga et al., 2001) probably because
the palmitoyl-moiety would hinder binding to CaM sterically.
Thus, its client selectivity could resemble that of PDE6D (PDEδ),
a trafficking chaperone that is important for K-Ras plasma
membrane localization (Chandra et al., 2011). Indeed, evidence
suggests that Ca2+/CaM can act as a trafficking chaperone for
K-Ras (Fivaz and Meyer, 2005; Grant et al., 2020a), which at high
concentration could sequester K-Ras from the membrane as it
binds with a lower affinity (KD = 4 µM) to nanodiscs than to
Ca2+/CaM (Gillette et al., 2015). Given that Ca2+/CaM has a
different K-Ras affinity, release mechanism, cellular distribution,
and probably client spectrum than PDE6D, it can be expected that
these proteins have overlapping, yet non-redundant chaperone
functions. The interaction of CaM with K-Ras is inhibited by the
phosphorylation of Ser181 in the C-terminus of K-Ras, while vice
versa CaM binding prevents phosphorylation (Alvarez-Moya
et al., 2010). Intriguingly, the phosphomimetic S181D has a
reduced stemness potential (Wang et al., 2015b). Consistently,
the atypical PKC agonist prostratin reduced the growth in several
murine tumor models, including pancreatic cancer cell line
derived xenografts (Wang et al., 2015b).
Thus, a novel rationale for the development of CaM inhibitors
has emerged, which is tied to the K-Ras-dependent induction
of cancer cell stemness. While this K-Ras and cancer stemness
association may rekindle CaM inhibitor drug development,
further dissection of the molecular mechanism is hampered by
the fact that three transcribed copies of CaM genes exist (CALM1-
3) in the human genome (Toutenhoofd and Strehler, 2000). CaM
cell biology is therefore difficult to dissect genetically.
Here we describe the identification of the formyl
aminobenzazulenone 1, later named Calmirasone1, as a
novel, covalent CaM inhibitor. The compound is synthetically
readily accessible in a six-step synthesis from commercially
available guaiazulene. Its higher CaM affinity, fast K-Ras directed
cellular activity, and > 40-fold reduced unspecific cell toxicity
as compared to OphA allow the utilization of Calmirasone1 in
acute cell biological experiments.
RESULTS
Phenotypic Assessment of Amino
Benzazulenones vs. Ophiobolin A
OphA is a potent CaM inhibitor that covalently inactivates its
target. We previously showed that it selectively inhibits the
functional membrane organization of oncogenic K-Ras. This
enabled the inhibition of cancer stem cell features by an as
yet not fully defined cellular mechanism (Najumudeen et al.,
2016). However, the broad toxicity of OphA limits its application
(Chidley et al., 2016).
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 July 2021 | Volume 9 | Article 665673
fcell-09-665673 July 6, 2021 Time: 12:35 # 3
Okutachi et al. A Covalent CaM-Inhibitor Tool Compound
In order to identify a less toxic functional analog of OphA
for application in cell biological studies, we chose the azulene-
derived aromatic benzazulen-3-one scaffold, which is distantly
related to the non-aromatic 5-8-5 tricyclic ring framework of
OphA. This choice was based only on the chemical similarity,
and no additional compound-design or -screening efforts
were made. We prepared two series of synthetically easily
accessible compounds, formylated and matching non-formylated
aminobenzazulenones, containing two or one electrophilic
functionality for covalent binding (Scheme 1). The ortho-
quinone methide electrophile is part of the ring structure
and was shown to react readily with primary amines in a
nucleophilic aromatic substitution reaction (Kiriazis et al., 2017;
Supplementary Data 1); however, other nucleophiles could also
react with it. In addition, formyl aminobenzazulenones can
undergo a typical Schiff base reaction with amines via their
C1-formyl, similar to OphA.
Given that toxicity was the major obstacle to overcome,
we first characterized the effects of the compounds in
phenotypic assays. Clonogenic growth of breast cancer cell
derived 3D tumor spheroids under low adherent conditions
is a well-established assay for cancer stem cell properties
(Dontu et al., 2003). We were interested in compounds with
high K-Ras selectivity in 3D spheroid assays, but low general
toxicity in 2D proliferation assays. Consistent with their Ras
mutation status, MDA-MB-231 (K-RasG13D) and Hs 578T (H-
RasG12D) spheroids were selectively sensitive to KRAS and
HRAS knockdown, respectively (Supplementary Figures 1A–D),
as shown previously (Siddiqui et al., 2020).
Compounds showed varying potencies in 3D spheroids
with IC50 values between 12 and > 40 µM in MDA-MB-
231, and 5.2 and > 40 µM in Hs 578T, as compared
to 0.3 and 1.8 µM, respectively, for OphA (Table 1 and
Supplementary Figures 1E–H). In order to have a more
robust descriptor of the compound effect on the clonogenic
sphere forming ability of these cells, we used the drug
sensitivity score, DSS3, which is a normalized area under the
dose-response curve value with superior accuracy over IC50
determination (Figures 1A,B; Yadav et al., 2014). Thus, it
became clear that some compounds had a selectivity for the
SCHEME 1 | Structures of OphA and the synthetic formyl aminobenzazulenones (1–7) and matching aminobenzazulenones (8–14).
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TABLE 1 | IC50 values of benzazulenones tested on 3D tumorosphere assay.
MDA-MB-231 Hs 578T
Compound IC50/µM logIC50 ± SD IC50/µM logIC50 ± SD
1 12 −4.92 ± 0.03 22.5 −4.65 ± 0.04
2 22.8 −4.64 ± 0.06 24.9 −4.61 ± 0.05
3 35 −4.46 ± 0.05 25.8 −4.6 ± 0.1
4 >40 Inconclusive >40 Inconclusive
5 34.5 −4.46 ± 0.05 13.2 −4.88 ± 0.04
6 >40 Inconclusive >40 Inconclusive
7 >40 Inconclusive >40 Inconclusive
8 32.4 −4.5 ± 0.5 10.6 −4.98 ± 0.03
9 19.6 −4.71 ± 0.03 17.4 −4.76 ± 0.01
10 >40 Inconclusive 23.1 −4.64 ± 0.04
11 15.4 −4.81 ± 0.05 5.2 −5.23 ± 0.04
12 >40 Inconclusive 8.5 −5.1 ± 0.1
13 >40 Inconclusive >40 Inconclusive
14 >40 Inconclusive >40 Inconclusive
OphA 0.3 −6.54 ± 0.02 1.8 −5.75 ± 0.02
Data represent mean of three biological repeats (Supplementary Figures 1E–H).
KRAS-dependent MDA-MB-231 spheroids that was similar to or
better than that of OphA.
Next we compared the general cytotoxicity (Figures 1C,D)
and antiproliferative activity in cells grown in 2D at 10
µM compound concentration (Supplementary Figures 1I,J).
Higher toxicities and antiproliferative effects with selectivity
for MDA-MB-231 were generally observed for the formyl
aminobenzazulenones. However, none of the compounds tested
at 10 µM was as non-specifically toxic as OphA at only 1 µM
against HRAS-dependent Hs 578T cells.
Several Benzazulenones Have a Higher
Affinity to CaM Than OphA
High affinity to the target typically reduces off-target toxicities
(Bedard et al., 2020). We therefore next determined the in vitro
affinity of the 14 compounds to the intended target CaM
using a fluorescence polarization assay previously developed
by us (Manoharan et al., 2019). This assay measures the
displacement of a fluorescein-labeled CaM-binding peptide, here
derived from plasma membrane calcium-ATPase (PMCA), from
purchased CaM by the inhibitors (Table 2 and Supplementary
Figures 2A,B).
Compounds 2 and 3 showed the highest affinity (15-fold
higher affinity than OphA) and 1 being third best (fourfold
higher affinity) after 24-h incubation. The fact that OphA had
a significantly higher cytotoxic and antiproliferative activity
(Figures 1C,D and Supplementary Figures 1I,J), despite lower
affinity than six of the compounds, confirms its problematic
off-target toxicity (Chidley et al., 2016).
Based on these in vitro and the phenotypic data, we calculated
a customized composite drug activity score to select compounds
with most favorable properties in each series, i.e., high overall
activity in the 3D spheroid assay, high MDA-MB-231 KRAS-
mutant cell line selectivity in 3D spheroid assays, low relative
2D growth toxicity against Hs 578T cells relatively to MDA-MB-
231, and high affinity (Supplementary Figures 2E,F). Thus, we
selected 1, 2, 3, 8, 9, and 11 for further analysis.
Of note, the binding affinity of OphA increased over
several hours, consistent with the slow covalent Schiff base
bond formation and the additional pyrrole adduct formation
(Figures 2A,B and Supplementary Scheme 1). By contrast, most
benzazulenones immediately showed high IC50 ranging from
submicromolar to tens of micromolar.
The potency and selectivity of covalent inhibitors are governed
by two parameters, namely K i, the dissociation constant of the
initial non-covalent complex, and k2, the rate of subsequent
covalent bond formation (Singh et al., 2011). The latter cannot
be too high to avoid non-specific reactivity. Analysis of the
reactivity of the top six compounds revealed that formyl
aminobenzazulenonens had lower K i as compared to non-
formylated compounds, suggesting that the formyl moiety
increases the non-covalent affinity component (Table 3 and
Supplementary Figures 2G,H). This is inconsistent with the
hydrophobic binding sites on CaM. However, k2 increased for 1
and 2, as well as 8 and 9, with both 2 and 9 having a covalent
bond rate constant as high as that of OphA, which also showed
an intermediate K i value.
Cellular BRET Experiments Confirm
K-Ras Selectivity of Top Compound 1
Ras proteins are tightly packed into proteo-lipid membrane
signaling complexes called nanoclusters (Abankwa et al., 2007).
Fluorescent tagging of Ras proteins with a pair of FRET-enabling
fluorophores thus leads to the emergence of nanoclustering-
dependent FRET. Loss of this FRET signal reports, however, not
only on the loss of nanoclustering but also on any upstream
processes, i.e., proper Ras plasma membrane trafficking or lipid
modifications (Kohnke et al., 2012).
Here we established an analogous nanoclustering-BRET
assay by tagging RasG12V proteins with Rluc8, enabling
donor emission, and GFP2 as an acceptor. As expected,
treatment with mevastatin, which blocks prenyl synthesis,
reduced nanoclustering-BRET of both Ras isoforms fairly
indiscriminately, while treatment with a farnesyl transferase
inhibitor (FTI-277) selectively (1.4-fold) decreased H-Ras
nanoclustering-BRET (Figures 3A,B), due to the alternative
prenylation of K-Ras, as described before (Kohnke et al., 2012).
The inhibition of the trafficking chaperone PDE6D, which
facilitates plasma membrane trafficking, in particular of K-Ras,
decreases selectively K-Ras nanoclustering-FRET (Siddiqui
et al., 2020). In agreement with CaM acting as a trafficking
chaperone that can likewise promote forward trafficking to the
plasma membrane, we observed a K-Ras selective reduction of
nanoclustering-BRET after CaM inhibition with calmidazolium
(1.5-fold) and OphA (1.2-fold). The atypical PKC agonist
prostratin, which would stimulate K-Ras-Ser181 phosphorylation
and thus block CaM binding, had a similar selectivity (1.5-fold)
as the CaM inhibitors.
We then tested the top six compounds in this assay in order
to directly assess their in cellulo K-Ras selectivity. While most
compounds appeared to show some level of K-Ras selectivity
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FIGURE 1 | Phenotypic assessment of anticlonogenic and cytotoxic activities of compounds. (A,B) A higher DSS3 reflects a more potent effect of formyl
aminobenzazulenones (A) and aminobenzazulenones (B) tested at a concentration range of 0.6–40 µM on KRAS-mutant MDA-MB-231 and HRAS-mutant Hs 578T
3D spheroid formation in low attachment condition without serum. Data represent mean values ± SD, n ≥ 3. Numbers above the bars indicate the KRAS/HRAS
mutant cell line DSS3 ratios. (C,D) The relative toxicity of formyl aminobenzazulenones (C) and aminobenzazulenones (D) was assessed in the CellTox Green assay.
Cells were grown as 2D adherent monolayers overnight and then treated for 72 h with 1 µM OphA or 10 µM of the indicated benzazulenones. Data represent mean
values ± SD, n ≥ 2. The statistical significance levels are annotated as *p < 0.05; **p < 0.01; ****p < 0.0001, or ns, not significant.
TABLE 2 | CaM-binding affinity of compounds after 24-h incubation.
Formyl aminobenzazulenones Aminobenzazulenones
Compound Kd ± SD/µM Compound Kd ± SD/µM
1 0.87 ± 0.02 8 3.1 ± 0.3
2 0.23 ± 0.01 9 1.44 ± 0.03
3 0.25 ± 0.02 10 Inconclusive
4 39 ± 12 11 0.81 ± 0.03
5 29 ± 7 12 6.1 ± 0.3
6 31 ± 10 13 62 ± 26
7 45 ± 4 14 21.4 ± 0.6
A fluorescence polarization assay with the fluorescently labeled PMCA peptide
as probe was performed. For comparison Kd(OphA) = 3.5 ± 0.2 µM. While
some compounds showed faint autofluorescence under the polarization assay
conditions, their emission was too weak as compared to that of fluorescein to
interfere with the measurements (Supplementary Figures 2C,D).
(all < 1.3-fold) when compared at 20 µM and 24-h exposure
(Figures 3A,B), testing over a wider concentration range
revealed distinct potencies and selectivities (Supplementary
Figures 3A,B). We employed the DSS analysis adapted to
BRET-data (BRET-DSS3) to quantify these activities (Figure 3C).
While, again, overall BRET-activity was highest for OphA, K-Ras
selectivity was highest for 1. All other compounds had lower and
non-significant selectivities. By doing a BRET donor saturation
titration analysis, we further confirmed that 1 has a similar K-Ras
vs. H-Ras selectivity as OphA (Figures 3 D,E and Supplementary
Figures 3C–F).
Compound 1 affinity to CaM changes less over time than
that of OphA, suggesting that it assumes its full activity faster
(Figure 2), which could be advantageous if true also in cellular
applications. We therefore tested this property in cells using the
K-Ras BRET biosensor. In order to see clear effects at short
exposure times, all compound concentrations were increased.
OphA showed no significant BRET change during the 2-h
treatment timeframe, consistent with the significant time it
requires for high affinity binding (Figure 2). Likewise, mevastatin
did not cause any reduction in the BRET signal, as it has
to block metabolic pathways for farnesyl- and geranylgeranyl-
pyrophosphate synthesis and therefore acts slowly after protein
turnover. In agreement with the in vitro data, 1 showed a
38% reduction in the BRET signal within 10 min of treatment
(Figure 3F). It was therefore even more active acutely in cells than
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FIGURE 2 | Benzazulenones have higher IC50 with less change over time as compared to OphA. Change of effective CaM-binding affinity over time of OphA and
formyl aminobenzazulenones (A) and aminobenzazulenones (B) as measured in the fluorescence polarization assay using F-PMCA peptide as the fluorescent probe.
Data represent mean values ± SD, n = 2. Binding curves are plotted in Supplementary Figures 2A,B. Derived rate analysis plots are in Supplementary
Figures 2G,H.
TABLE 3 | Analysis of K i and k2 and the second-order rate constant k2/K i from
data plotted in Figure 2 and processed as described.
Compound k2 ± SD/h−1 Ki ± SD/µM k2/Ki/M−1 h−1
OphA 1.09 ± 0.04 79 ± 8 14 × 103
1 0.51 ± 0.09 52 ± 29 10 × 103
2 1.18 ± 0.09 13 ± 4 93 × 103
3 0.45 ± 0.07 11 ± 6 42 × 103
8 0.35 ± 0.03 39 ± 10 9 × 103
9 1.3 ± 0.2 229 ± 67 6 × 103
11 0.29 ± 0.05 78 ± 34 4 × 103
the non-covalent CaM inhibitor trifluoperazine (Kd = 1.35 µM)
or calmidazolium (Kd = 13.5 nM) (Manoharan et al., 2019).
BRET Experiments Confirm K-Ras/CaM
Disrupting on-Target Activity in Cells
Previously, a preference of CaM binding to active GTP-K-
Ras was observed (Villalonga et al., 2001; Abraham et al.,
2009). In agreement with these data, we observed in cells a
higher BRET of N-terminally Rluc8-tagged K-RasG12V with
GFP2-CaM than that of non-oncogenic K-Ras (Figure 4A and
Supplementary Figure 4). Likewise, higher BRET levels were
confirmed with three additional oncogenic mutants of K-Ras
(Figure 4B and Supplementary Figures 4A,B). Furthermore, in
line with previous reports (Villalonga et al., 2001), K-RasG12V
(BRETmax = 0.35 ± 0.02) displayed a significantly (p = 0.001,
unpaired t-test) higher cellular BRET ratio with GFP2-CaM than
H-RasG12V did (BRETmax = 0.20 ± 0.02), which remained
at or below control levels (Figure 4C and Supplementary
Figure 4). This could explain the preferential effect on K-Ras
nanoclustering-BRET by CaM inhibitors (Figure 3).
In order to have a high dynamic range of the BRET signal,
we used the Rluc8-K-RasG12V/GFP2-CaM BRET pair to directly
assess the effect of modulators of the K-Ras/CaM interaction.
Both CaM inhibitor calmidazolium and OphA significantly
reduced the BRET signal. Surprisingly, prostratin did not have
an effect at the tested concentration (Figure 4D).
To further delineate the structural requirements for the on-
target, K-RasG12V/CaM disrupting activity, we tested formyl
aminobenzazulenone 1 in comparison to the closely related, but
less active aminobenzazulenone derivative 8, which lacks the C1-
formyl group. Compound 1 (IC50 = 31± 2 µM) was significantly
more active than 8 (IC50 = 70 ± 11 µM; p = 0.03), also when
tested over a wider concentration range (Figure 4E). Yet, OphA
remained the most effective compound in this cellular assay after
a 24-h-long exposure (IC50 = 12± 2 µM).
Dependence of the Activity of top
Compound 1 on Lysines 75, 77, and 148
of CaM
We previously showed that the K-Ras directed effect of OphA
is abolished if a lysine mutant of CaM is expressed to rescue
the knockdown of endogenous CaM (Najumudeen et al., 2016).
In this mutant CaM (mutCaM), lysines 75, 77, and 148 were
replaced by glutamine, i.e., those residues that were reported
to be modified by OphA (Kong Au and Chow Leung, 1998).
To assess the dependence of compound 1 binding to CaM
on these lysine residues, we again employed a fluorescence
polarization assay using in-house purified, His-tagged CaM
or mutCaM. Both variants bound to the fluorescein-labeled
peptide of Ca2+/calmodulin-dependent kinase II (CaMKII)
(Manoharan et al., 2019). As observed before (Figure 2), the
affinity of OphA to wild-type (wt) CaM increased over several
hours, while no binding was observed to mutCaM (Figure 5A
and Supplementary Figures 5A,B), as reported previously
(Najumudeen et al., 2016; Manoharan et al., 2019). By contrast,
compound 1 also displayed binding to mutCaM; however, as
compared to wt CaM, the affinity did not increase over time
(Figure 5B and Supplementary Figures 5E,F). This was different
for the non-formylated counterpart 8, which showed the same
binding affinity for wt CaM and mutCaM over time (Figure 5C
and Supplementary Figures 5E,F). The comparison of the
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FIGURE 3 | Nanoclustering-BRET assays confirm K-Ras selectivity and fast intracellular activity of compound 1 in cells. (A,B) Testing of top six benzazulenones at
20 µM and 24-h exposure in K-RasG12V (A) and H-RasG12V (B) nanoclustering-BRET assays. Controls are FTI-277 (1 µM), OphA (2.5 µM), mevastatin (10 µM),
calmidazolium (20 µM), and prostratin (10 µM). The acceptor/donor (A/D) plasmid ratio of GFP2- and Rluc8-tagged RasG12V was 4/1. Data represent mean
values ± SD, n = 3. (C) BRET-DSS3 values for selected six benzazulenones and OphA, derived from dose response analysis of benzazulenones (0.1–80 µM) and
OphA (0.3–20 µM) on K-RasG12V and H-RasG12V nanoclustering-BRET data (Supplementary Figures 3A,B). Numbers above the bars indicate the
K-RasG12V/H-RasG12V BRET-DSS3 ratios. The A/D plasmid ratio was 4/1. Data represent mean values ± SD, n ≥ 3. (D) K-RasG12V and (E) H-RasG12V
nanoclustering-BRET donor saturation titration curves showing the effect of OphA (2.5 µM), 1 (20 µM), and vehicle control. Data represent mean values ± SD, n = 2.
Note that error bars are very small and may not be recognizable. BRETmax data represent mean values ± SD, n = 2. (F) Time-dependent change of K-RasG12V
nanoclustering-BRET signal after treatment with 1 (50 µM), OphA (10 µM), mevastatin (10 µM), trifluoperazine (20 µM), and calmidazolium (20 µM). The A/D plasmid
ratio was 4/1. Data represent mean values ± SD, n ≥ 2. The statistical significance levels are annotated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, or
ns, not significant.
activities of all three compounds suggests that the K75Q, K77Q,
and K148Q mutations in the mutCaM have rendered CaM
partially insensitive to 1 and 8 binding. It furthermore shows that
the lysine-dependent increase in affinity over time of compound
1 depends on the C1-formyl, which could form a Schiff base bond
in a slow reaction.
Activity in Cell Proliferation Assays
Correlates With the K-Ras Dependence
of Cancer Cell Lines
Unspecific, broad toxicity against KRAS (MDA-MB-231, MIA
PaCa-2) and HRAS mutant (Hs 578T, T24) cancer cell lines,
as well as HEK293-EBNA cells, is a major issue of OphA
(Figure 6A). This broad toxicity appears to greatly contribute
to the high “anti-cancer cell activity” that is observed with this
compound and clearly contrasts to the KRAS mutant cancer
cell line selectivity seen with calmidazolium and 1 (Figure 6B
and Supplementary Figures 6A–E). Of note, the latter has a
background activity against HRAS mutant cancer cells that was
as low as that of the covalent K-RasG12C inhibitor AMG-510.
When compounds were compared in 3D spheroid growth
assays, the significant potency difference between clinical
compounds and 1 became, however, more obvious than in 2D
assays. Both AMG-510 and vemurafenib selectively and potently
abolished the growth of the K-RasG12C- and BRAF-V600E-
mutant cancer cell 3D spheroids, respectively, with basically
no activity against other cancer cell spheroids (Figure 6C and
Supplementary Figures 6F–I). Compound 1 had a visibly lower
activity, yet the activity profile seemed to correlate with the KRAS
dependence of the cancer cell lines (Figures 6C,D). Again, OphA
appeared highly potent, yet clearly at the cost of its broad toxicity
(Figures 6A,C). These data are in line with a much improved
on-target activity of 1 as compared to OphA.
The Best Tool Compound 1 Can Be
Utilized in Cell Biological Experiments
Given the significantly reduced unspecific toxicity of 1 as
compared to OphA, we tested its application in cell biological
experiments. CaM dynamically localizes to centrosomes, spindle,
and other structures during mitosis, and its inhibition is known
to affect proper cleavage furrow formation, which can lead to
multipolarity (Yu et al., 2004; Wu et al., 2010).
In order to track this phenotype and the CaM distribution,
we transfected HeLa cells with a mCherry-CaM construct, which
primarily localized to centrosomes in mitotic cells (Figure 7A).
When these cells were synchronized and treated with the
potent, non-covalent CaM inhibitor calmidazolium, an increased
fraction of multipolar cells with multiple mCherry-CaM-positive
centrosomes was observed. As expected from the faster in-
cell activity observed in BRET experiments (Figure 3F), this
phenotype was significantly pronounced with 1 (Figure 7B),
confirming its utility in cell biological experiments. Finally,
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FIGURE 4 | Cellular K-RasG12V/CaM interaction BRET confirms on-target activity of compound 1 in cells. (A) BRET donor saturation titration curves between
Rluc8-K-Ras or Rluc8-K-RasG12V and N-terminally GFP2-tagged CaM. (B) BRET donor saturation titration curves between the Rluc8-tagged K-Ras oncogenic
mutants (K-RasG12C, K-RasG13D, and K-RasQ61H) with GFP2-CaM. The BRETmax data represent mean values ± SD, n ≥ 2. (C) BRET donor saturation titration
curves between Rluc8-K-RasG12V or Rluc8-H-RasG12V and GFP2-CaM. Plasmids expressing Rluc8 and GFP2 proteins alone were used as controls for
non-specific interaction. (D) Compounds calmidazolium (20 µM), prostratin (20 µM), or OphA (5 µM), as well as formyl aminobenzazulenone 1 (20 µM) or
non-formylated counterpart aminobenzazulenone 8 (20 µM) were tested using the Rluc8-K-RasG12V/GFP2-CaM BRET reporter. The A/D plasmid ratio was 9/1.
Data represent mean values ± SD, n ≥ 2. (E) Dose-response analysis of compound 1 and its non-formylated derivative 8 as compared to OphA using
Rluc8-K-RasG12V/GFP2-CaM BRET signal. The A/D plasmid ratio was 9/1. Data represent mean values ± SD, n ≥ 2. The statistical significance levels are
annotated as *p < 0.05; ***p < 0.001, or ns, not significant.
we named compound 1, the best performing tool compound,
Calmirasone1.
DISCUSSION
We have here identified compound 1, which we named
Calmirasone1, a synthetically well-accessible, high affinity
covalent CaM inhibitor with fast cellular K-Ras selectivity
and significantly lower toxicity than the natural product
counterpart OphA. While the current potency and properties
of Calmirasone1 do not fit for a compound with future
medical applications, our data support its intended utility
as a tool compound in cell biological applications to study
CaM-dependent cellular processes. Such tool compounds are
important also for drug development, as they can foreshadow
some on-target issues and reveal crucial mechanistic features of
actual drug candidates.
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FIGURE 5 | Assessment of lysine-dependent CaM-binding activity of OphA, formyl aminobenzazulenone 1, and aminobenzazulenone 8. Time course of
lysine-dependent CaM-binding activity of OphA (A), compound 1 (B), and compound 8 (C) as measured in the fluorescence polarization assay using F-CaMKII
peptide as the fluorescent probe. OphA displayed negligible binding with mutCaM compared to wtCaM; hence, no IC50 values could be derived (Supplementary
Figures 5A,B).
FIGURE 6 | Benchmarking of top compound 1 in several cancer cell lines. (A) The relative 2D viability of various cell lines following single dose treatment with
AMG-510 (1 µM), calmidazolium (2.5 µM), OphA (1 µM), and 1 (10 µM) was assessed using the alamarBlue assay. Cells were grown as 2D adherent monolayers
overnight and then treated for 72 h with indicated compounds. Data represent mean values ± SD, n ≥ 3. (B) DSS3 measuring the effects of AMG-510 (0.003–40
µM), calmidazolium (0.3–40 µM), OphA (0.3–40 µM), and 1 (0.6–80 µM). Cells were grown as 2D adherent monolayers overnight and then treated for 72 h. Results
represent mean values ± SD, n = 3. (C) DSS3 measuring the effects of AMG-510 (0.6–40 µM), vemurafenib (0.3–20 µM), prostratin (0.6–80 µM), OphA (0.3–20
µM), and 1 (1.3–80 µM). Cells were grown as 3D spheroids for 72 h then treated with compounds for another 72 h before alamarBlue viability measurements. Data
represent mean values ± SD, n ≥ 2. (D) Heatmap of ATARiS gene sensitivity scores obtained from the project DRIVE database for KRAS-dependent cell lines (MIA
PaCa-2, NCI H358, and MDA-MB-231) and HRAS-dependent cell lines (Hs 578T and T24). Negative values (red) indicate sensitivity of the cell line proliferation to the
knockdown of shown genes, while positive (blue) indicates the opposite.
Several of our compounds bound to CaM with submicromolar
affinity, with Calmirasone1 binding four times better than
OphA. Comparison of Calmirasone1 and 8 affinities with
purified wt and mutant CaM suggests that the affinity binding
component that remained constant over time was independent
of the C1-formyl (Figure 5). This immediate high affinity
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FIGURE 7 | Phenotypic effects of CaM inhibitors on centrosome numbers. (A) Representative images for bipolar normal (DMSO 0.5%, top) and multipolar
centrosomes in HeLa cells after acute treatment for 2 h with calmidazolium (20 µM, middle) 1 (50 µM, bottom). Hela cells expressing mCherry-wtCaM (red) cells
were synchronized with nocodazole to the G2/M phase for 16 h. Then cells were treated with compounds and simultaneously with the protease inhibitor MG132 (10
µM). Arrows indicate predominant localization of mCherry-wtCaM on the centrosomes during mitosis. DNA was stained with DAPI (blue). Scale bar, 5 µm. (B) The
multipolar phenotype was quantified for each treatment from images containing 35 to 70 cells per condition. Data represent mean values ± SD, n = 3. Statistical
significance was evaluated with Fisher’s exact test. The statistical significance levels are annotated as **p < 0.01, or ns, not significant.
could have been of non-covalent or actually also of covalent
nature. Given that a second reactive group with covalent binding
potential (ortho quinone-methide, o-QM) is present in both
Calmirasone1 and 8, it is possible that this electrophile mediates
additional covalent binding to lysine residues other than those
three mutated lysines in mutCaM (Supplementary Data 1), or
alternatively cysteines. However, nucleophilic cysteines are not
present in the studied CaM variants. Based on previous synthetic
studies, the o-QM reactivity toward nucleophiles (amino or thiol)
can be very fast (within minutes) and proceeds via a nucleophilic
aromatic substitution (SNAr-type) reaction (Kiriazis et al., 2017).
We currently lack evidence whether this second electrophile is
also engaged covalently.
Our rate analysis (Table 3) shows that the compound with
the highest second order rate constant was 2, followed by 3.
However, as our cellular BRET-data in Figure 3C indicate, this
increased reactivity appears to come at the cost of selectivity.
We see a maximal selectivity for K-RasG12V vs. H-RasG12V
for 1, which has intermediate parameters, in agreement with a
balance between sufficient affinity and a moderate reactivity. In
agreement with the slow Schiff-bond formation, we find rate
constants that are several thousand-fold lower than those of
Lys-reactive compounds with a vinyl sulfone as warhead, such
as the CDK2-inhibitor NU600 (k2/Ki = 5.0 × 103 M−1 s−1)
(Anscombe et al., 2015). However, the α-hemoglobin targeting
compound GBT440 (Voxelotor) with a formyl warhead similar
to our compounds has a second-order rate constant comparable
to what we found for our benzazulenones (k2/Ki = 15 × 103
M−1 h−1) (Center for Drug Evaluation and Research, 2017;
Metcalf et al., 2017).
We speculate that the formyl-independent binding
component significantly improves the unspecific toxicity of
compounds Calmirasone1 and 8 (Figures 1C,D). However, the
major, slower affinity increase stems from the C1-formyl and
depends on mutated lysines 75, 77, and 148. This is consistent
with the formyl as a hard electrophile reacting with lysine as
a hard nucleophile. The typically slow Schiff base formation
may, therefore, explain the slow increase in the effective affinity
(Figure 5B). The formyl substituent is furthermore beneficial,
as it lowers the relatively high clogP, thus potentially increasing
water solubility of these not very drug-like molecules. However,
drug entry into cells can be an active process that depends on
transporters from the solute carrier protein (SLC) family (Girardi
et al., 2020). In addition, passive entry is typically characterized
by the compound specific partitioning coefficients. Both passive
and active entry may explain why we observed distinct time
courses for the inhibitors to become active in cells against
K-RasG12V membrane anchorage (Figure 3F).
Currently, the structural basis for CaM inhibition by OphA is
not known. However, similar to other non-covalent inhibitors,
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such as trifluoperazine, the conformational dynamics of CaM
may change dramatically upon inhibitor binding, collapsing
the original dumbbell-shaped molecule into a compact globular
structure (Vandonselaar et al., 1994). We speculate that covalent
inhibitors such as OphA and the here tested compounds would
have a similar effect on the conformation and therefore activity
of CaM to bind its canonical and non-canonical clients, such
as K-Ras.
The Ras nanoclustering-dependent BRET assay that we used
before successfully in the FRET format to assess the Ras selectivity
close to the mechanistic target K-Ras (Najumudeen et al., 2016;
Posada et al., 2016) is sensitive to the disruption of Ras membrane
anchorage and correct plasma membrane trafficking. CaM was
recently established as a K-Ras trafficking chaperone, which
can essentially act as a solubilizing factor to shield the farnesyl
tail from the aqueous environment of the cytoplasm (Grant
et al., 2020a). Therefore, the drop in K-Ras nanoclustering-BRET
with CaM inhibitors is consistent with CaM being a trafficking
chaperone for K-Ras (Grant et al., 2020b).
We have previously demonstrated similar changes in
membrane anchorage of K-Ras with the inhibition of PDE6D,
another prominent trafficking chaperone of K-Ras (Siddiqui
et al., 2020). For PDE6D, clients such as H-Ras that are
in addition palmitoylated cannot bind as long as they are
palmitoylated (Chandra et al., 2011; Dharmaiah et al., 2016).
This establishes an effective K-Ras over H-Ras selectivity for
PDE6D inhibition-induced cell growth effects (Siddiqui et al.,
2020). Grant et al. (2020a) recently derived singly lipidated
polybasic termini of proteins as non-canonical CaM interaction
sequences. Consistently, K-Ras but not H-Ras or N-Ras bind
to CaM (Villalonga et al., 2001). It can be speculated that any
additional palmitoylation would sterically hinder access to CaM,
making palmitoylated Ras isoform clients only if they are in
their non-palmitoylated state (Agamasu et al., 2019). This would
explain why the potent CaM inhibitor calmidazolium decreased
the BRET signal of H-Ras, albeit to a lesser extent than that of
K-Ras (Figures 3A,B).
The highly potent calmidazolium, as well as the covalent
inhibitors OphA and Calmirasone1, significantly disrupted
K-Ras/CaM-BRET in cells. By contrast, the PKC agonist
prostratin had no effect on K-Ras/CaM-BRET, but on
K-RasG12V nanoclustering BRET. It may therefore be
that prostratin exerts its K-Ras selectivity by a different
mechanistic route than the inhibition of K-Ras/CaM interaction.
Interestingly, prostratin had almost no effect on cell growth in
3D spheroid assays (Figure 6C).
Clonogenic 3D spheroid growth depends on stemness
associated asymmetric and symmetric division processes of
cancer cells with stemness traits (Cicalese et al., 2009).
Accordingly, Calmirasone1 demonstrates an efficacy against 3D
spheroid growth that correlates with the KRAS dependence of
the tested cell lines. In this regard, it is noteworthy that the
DSS3 potency of Calmirasone1 reaches already approximately
50% of AMG-510, the K-RasG12C inhibitor that is currently
being evaluated in the clinic (Hong et al., 2020). However,
a much larger number of cell lines would have to be tested
to demonstrate a correlation between compound activity and
anticipated K-Ras/CaM targeting mechanism. For instance, both
cell lines that were employed here also carry mutations in BRAF
(MDA-MB-231) or in TP53 (both MDA-MB-231 and Hs578T).
For both B-Raf and p53, connections to CaM signaling have been
reported (Ren et al., 2008; Taylor et al., 2020); hence, the cell
killing activity may relate to multiple pathways that are affected
downstream of CaM.
In addition, we could demonstrate the benefits of using
Calmirasone1 as a tool compound in cell biological experiments,
which are not possible with OphA due to its high toxicity. We
observed the induction of multipolar cells by CaM inhibitor
treatment. Inhibition of CaM affects multiple processes during
cell division, notably cleavage furrow formation (Yu et al.,
2004). While failure of cytokinesis can lead to chromosomal
instability and therefore a hallmark of cancer cells, the exact
nature of the multipolar phenotype and additional effects could
also play a role in the ultimately cell growth inhibiting effect
of CaM inhibition (Wu et al., 2010). Interestingly, a different
compound that induces multipolar acentrosomal spindles was
found to selectively kill tumor cells (Wang et al., 2015a). In our
cell biological experiments, Calmirasone1 (Kd = 0.87 ± 0.02
µM) can be considered more effective than non-covalent
calmidazolium (Kd = 13.5 nM) (Figures 3F, 7B). While
Calmirasone1 was used at 2.5-fold higher concentration, the 64-
fold affinity difference between these two compounds suggests
a > 25-fold higher effectivity of Calmirasone1. Therefore,
Calmirasone1 can be used to acutely (within 30–60 min) perform
a chemical knockdown of CaM in cells in a more efficient manner
than with the most potent non-covalent inhibitor calmidazolium.
Covalent inhibitors have experienced a renaissance in the past
few years (Singh et al., 2011). Our novel covalent CaM inhibitor
Calmirasone1 will add to the arsenal of covalent tool compounds




Synthesis of chemical compounds and their analytical
information are given in Supplementary Data 1.
Expression Constructs and siRNA
Most expression constructs described in the study were produced
by multisite gateway cloning as described (Wall et al., 2014;
Supplementary Table 1). For plasmids used in the BRET assay,
three entry clones, with compatible LR recombination sites,
encoding the CMV promoter, Rluc8, or GFP2 tag, and the
gene of interest were recombined with a destination vector,
pDest-305 or pDest-312, using the Gateway LR Clonase II
enzyme mix (cat. no. 11791020, Thermo Fisher Scientific). The
reaction mix was transformed into the ccdB-sensitive E. coli
strain DH10B (cat. no. EC0113, Thermo Fisher Scientific),
and positive clones were selected using ampicillin. pDest527-
His-wtCaM and pDest527-His-mutCaM were produced from
the LR reaction between the pDest-527 vector with either
entry clone pDONR221-wtCaM or pDONR221-mutCaM. The
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N-terminally GFP2-tagged CaM plasmid pDest-CMV-GFP2-
CaM was cloned at Genecust (France) and amplified in the
E. coli CopyCutter EPI-400 strain (cat. no. C400CH10, Lucigen)
according to the instruction of the manufacturer. All the plasmids
were verified by sequencing. Expression and localization of
the Ras and CaM fusion proteins were confirmed by confocal
microscopy (Supplementary Figure 7). Protein sequences of
all expression constructs are given in the Supplementary
Material section. pmCherry-wtCaM was previously described
(Manoharan et al., 2019).
Knockdown of CALM1 was done using a master mix of
multiple siRNA against the CALM1 transcript [QIAGEN
Hs_CALM1, siRNAs: SI00092925 (CALM1_4), SI02224215
(CALM1_5), SI02224222 (CALM1_6), and SI03649268
(CALM1_8)]. For the knockdown of specific Ras isoforms,
we used KRAS (K-Ras4A + K-Rras4B- L-005069-00) and HRAS
(L-004142-00) Dharmacon On-Target plus siRNA SMARTpools.
Scrambled siRNA control was from QIAGEN (cat. no. 102276).
Commercial Chemical Inhibitors
Fluorescein-labeled CaMKII and PMCA peptide were from
Pepmic, China, and Genscript, United States, respectively
(Manoharan et al., 2019). DMSO was from PanReac-AppliChem
(cat. no. A3672, ITW Reagents). Sources of the inhibitors used in
the study are listed below.
Compound Source Catalog number
Ophiobolin A Santa Cruz sc-202266
Mevastatin Alfa Aesar J61357
FTI-277 BioVision 2874
Prostratin Sigma-Aldrich P0077
Calmidazolium Santa Cruz sc-201494
AMG-510 MedChem Express HY-114277
Vemurafenib Selleckchem S1267
Trifluoperazine Cayman 15068
Benzethonium chloride Sigma-Aldrich 53751
RT-qPCR Analysis of Gene Transcript
Knockdown
MDA-MB-231 and Hs 578T cells were seeded in 12-well
plates and transfected with indicated amounts of siRNAs.
Where required, siRNA was transfected into cells using
a Lipofectamine RNAiMAX (cat. no. 13778075, Thermo
Fisher Scientific) reagent according to the instruction of the
manufacturer. After 24 h of transfection, total RNA was
isolated using NucleoZol (cat. no. 7040404, Macherey-Nagel)
according to the manufacturer protocol. Reverse transcription
was performed with 1 µg of total RNA using SuperScript
III Reverse Transcriptase (cat. no. 18080093, Thermo Fisher
Scientific). The knockdowns of KRAS, HRAS, and CALM1
gene transcripts were analyzed by real-time qPCR using
SsoAdvanced Universal SYBR Green Supermix (cat. no. 1725274,
BIO-RAD) on the CFX-connect real-time PCR instrument
(BIO-RAD). The transcripts were selectively amplified using
specific primers producing amplicons for total KRAS (both
KRAS4A and KRAS4B), HRAS, and CALM1. The gene
transcript ACTB encoding for β-actin was used as reference.
The following primers were used (Tsai et al., 2015): for
total KRAS, forward 5′-tacagtgcaatgagggacca-3′, reverse 5′-
tcctgagcctgttttgtgtct-3′ (amplicon 206 bp); for HRAS, forward
5′-ctgaccatccagctgatcca-3′, reverse 5′-tggcaaacacacacaggaag-3′
(amplicon 196 bp); for ACTB, forward 5′-ggggtgttgaaggtctcaaa-
3′; reverse 5′- ggcatcctcaccctgaagta-3′ (amplicon 203 bp); for
CALM1, forward 5′-gctcgcaccatggctgat-3′, reverse 5′- tgttggg
ttctgacccagtg-3′ (amplicon 144 bp).
3D Spheroid Assays
3D spheroid formation assays were performed in 96-well low-
attachment, suspension culture plates (cat. no. 655185, Cellstar,
Greiner Bio-One) under serum-free condition. About 1,000
(MDA-MB-231, NCI-H358, and MIA PaCa-2) or 2,500 (Hs
578T) cells per well were seeded in 50 µl of either an
RPMI medium (cat. no. 52400-025, Gibco, Thermo Fisher
Scientific) (MDA-MB-231, A375, and NCI-H358) or DMEM
(cat. no. 41965-039, Gibco, Thermo Fisher Scientific) (Hs 578T
and MIA PaCa-2), containing 0.5% MethoCult (cat. no. SF
H4636, Stemcell technologies), 1x B27 (cat. no. 17504044,
Gibco, Thermo Fisher Scientific), 25 ng/ml EGF (cat. no.
E9644, Sigma-Aldrich), and 25 ng/ml FGF (cat. no. RP-8628,
Thermo Fisher Scientific). Cells were cultured for 3 days and
then treated with compounds or vehicle control (DMSO 0.1%
v/v in growth medium) for another 3 days. The cells were
supplemented with a fresh growth medium on the third day
together with the drug treatment. For knockdown experiments,
cells were seeded in 12-well plates and treated with either 50
nM scrambled siRNA (cat. no. 1022076, QIAGEN) or indicated
concentrations of siRNAs. Next day, cells were collected by
trypsinization and re-plated into 96-well plates for 3D spheroid
suspension culture.
Spheroid formation efficiency was analyzed by an alamarBlue
assay reagent (cat. no. DAL1100, Thermo Fisher Scientific).
A 10% final volume of the alamarBlue reagent was added to
each well of the plate and incubated for 4 h at 37◦C. Then
the fluorescence intensity was measured using the FLUOstar
OPTIMA plate reader (BMG Labtech, Germany) with an
excitation wavelength of 560± 5 nm and an emission wavelength
of 590 ± 5 nm. The obtained fluorescence intensity data were
normalized to vehicle control corresponding to 100% sphere
formation and the signal after 100 µM benzethonium chloride
treatment, which killed all cells (i.e., maximum inhibition of
sphere formation).
Drug Sensitivity Score (DSS) Analysis
To quantitatively profile the drug sensitivity with a more robust
parameter than the IC50 or EC50 values, the drug sensitivity
score (DSS) analysis was employed. DSS values are essentially
normalized area under the curve (AUC) measures of dose-
response inhibition data (Yadav et al., 2014). Drug response data
files (in Excel) ready for online analysis were prepared according
to the example file obtained from the DSS pipeline website, called
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Breeze1 (Potdar et al., 2020). Either raw fluorescence intensity
measurements or normalized % inhibition data (for BRET assay
analysis) were uploaded.
The output file provides several drug sensitivity measures
including EC50 and AUC. We plotted the DSS3 value (Yadav et al.,




where DSS2 is given by the equation DSS2 = DSS1log a
and DSS1 is given by the equation DSS1 = AUC−t(x2− x1)(100−t)(Cmax−Cmin)
DSS3 was employed to emphasize drugs that obtain their
response area over a relatively wide dose window, as compared
to drugs that show increased response only at the higher end of
the concentration range. After logistic fitting of the dose-response
inhibition data, the area under the curve (AUC) was determined
as the exact solution. A 10% minimal activity threshold (t) was
set. The maximum (Cmax) and minimum (Cmin) concentrations
were used for screening of the inhibitors, with Cmax = x2
and x1 concentration with minimal activity t. The parameter
a is the value of the top asymptote, which can be different
from 100% inhibition as obtained from 100 µM benzethonium
chloride treatment.
2D Cell Toxicity and Viability Assays
Hs 578T and MDA-MB-23 cells cultured in complete DMEM
and RPMI medium [i.e., supplemented with 10% FBS (cat. no.
10270–098, Gibco, Thermo Fisher Scientific), 2 mM L-glutamine
(cat. no. 25030-024, Thermo Fisher Scientific)], respectively,
were plated onto 96-well F-bottom cell culture plates (cat.
no. 655180, Cellstar, Greiner Bio-One) at a density of 1,000
cells (MDA-MB-231, MIA-PaCa-2, T24, and HEK293-EBNA)
and 2,500 cells (Hs 578T) per well grown for 24 h. Freshly
thawed aliquots of test compounds were then added at indicated
concentrations. DMSO 0.2% v/v in a growth medium was used
as the vehicle control. Plates were further incubated for 72 h.
The cell viability and cell toxicity effects were analyzed by
alamarBlue and CellTox Green (cat. no. G8743, Promega) assays,
respectively. A 10% final volume of the alamarBlue reagent
was added to each well of the plate and incubated for 4 h
at 37◦C. Then the fluorescence intensity was measured using
the FLUOstar OPTIMA plate reader (BMG Labtech) with an
excitation wavelength of 560± 5 nm and an emission wavelength
of 590 ± 5 nm. The obtained fluorescence intensity data were
normalized to vehicle control (100% viability).
For the CellTox Green assay, 100 µl of the 2× CellTox Green
reagent was added to each well of a 96-well plate containing
100 µl of the medium. The plate was protected from light and
incubated for 15 min at 37◦C, then orbitally shaken for 1 min
at 700–900 rpm. The fluorescence intensity was measured using
the Clariostar plate reader (BMG Labtech) with an excitation
wavelength of 485 ± 4 nm and an emission wavelength of
530 ± 4 nm. The obtained fluorescence intensity data were
normalized to vehicle control (0% toxicity).
1https://breeze.fimm.fi/
Protein Purification
Our numbering of CaM follows (Kong Au and Chow Leung,
1998) with Ala being the first amino acid in human CaM,
as the N-terminal methionine of CaM is removed in most
organisms (Halling et al., 2016). His-wtCaM and His-mutCaM
were expressed in E. coli BL21 Star (DE3)pLysS (cat. no. C602003,
Thermo Fisher Scientific). pDest527-His-wtCaM and pDest527-
His-mutCaM plasmids encoding wild-type human CaM and
CaM with K75Q, K77Q, and K148Q mutations, respectively, were
transformed into E. coli BL21 Star (DE3)pLysS and grown in a
Luria Broth medium supplemented with ampicillin (100 µg/ml).
At A600 of 0.6–0.8, the culture was induced with 0.5 mM of
isopropyl β-D-thiogalactopyranoside and expressed for 16 h at
25◦C. Cells were collected by centrifugation and incubated on
ice for 30 min. The cell suspension was sonicated in a lysis
buffer (20 mM HEPES, pH 7.6, 150 mM NaCl, 5 mM MgCl2,
0.5 mg/ml lysozyme, and DNase I). The lysates were clarified by
centrifugation at 18,000 g for 30 min at 4◦C. The soluble fractions
were subjected to protein purification.
The His-tagged proteins were purified on HisTrapTM HP
Prepacked Columns (GE Healthcare) using the chromatography
system ÄKTAprime plus (GE Healthcare). The columns were
equilibrated in a buffer composed of 50 mM Tris HCl, pH
7.5, 150 mM NaCl, and 35 mM imidazole, and the His-tagged
proteins were eluted in an elution buffer containing 250 mM
of imidazole. The eluted fractions were dialyzed for 16 h at
4 ◦C in a buffer composed of 50 mM Tris HCl, pH 7.5,
150 mM NaCl, and 2 mM CaCl2. Protein concentration was
measured using a NanoDrop 2000c Spectrophotometer (Thermo
Fisher Scientific), and purified proteins were analyzed on a 4–
12% NuPAGE gel (cat. no. NP0321, Thermo Fisher Scientific)
(Supplementary Figure 8).
Fluorescence Polarization Assay
Fluorescence polarization (FP) assays were performed as
described (Manoharan et al., 2019). The IC50 of compounds were
determined in a binding/displacement assay using fluorescein-
labeled PMCA peptide (derived from plasma membrane Ca2+
transporting ATPase, a CaM binding protein) as the probe and
recombinant bovine calmodulin (cat. no. 208690, Merck), which
has an amino acid sequence identical to the human isoform.
The F-CaMKII peptide was used at 5 nM concentration with
50 nM of His-tagged wt and mutCaM. FP assays were carried
out in a black low volume round bottom 384-well plate (cat. no.
4514, Corning) with a reaction volume of 20 µl. Compounds
were threefold-diluted in an assay buffer (20 mM Tris Cl pH 7.5,
50 mM NaCl, 1 mM CaCl2, and 0.005% Tween 20), and a complex
of 100 nM CaM and 10 nM F-PMCA peptide was added. The
FP signals were recorded on the Clariostar (BMG labtech) plate
reader with excitation at 482± 8 nm and emission at 530± 20 nm
at 25◦C, after 30–60-min interval for up to 5 h. Then the plate was
incubated overnight at 4◦C, and the next day, final readings were
taken after a total of 24 h incubation. The fluorescence anisotropy
was calculated and plotted against the logarithm of the compound
concentration and fit to the log inhibitor vs. response–variable
slope (four parameters) equation in Prism (GraphPad). The IC50
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of the inhibitor was converted into Kd as described in Sinijarv
et al. (2017) using the equation
Kd =
[I]50
1 + [P]50KD,probe +
[E]0
KD,probe
where [I]50 is the concentration of the free inhibitor at 50%
displacement, given as [I]50 = IC50 − [EI]50, where [EI]50 is
the concentration of the CaM:inhibitor complex in case of 50%
displacement; [P]50 is the concentration of the free probe at
50% displacement; [E]0 is the concentration of free CaM at 0%
displacement; and KD,probe is the dissociation constant of the
complex of the probe and CaM. The KD of the probe, F-PMCA
to CaM, is 6 nM (Manoharan et al., 2019).
The potency of the irreversible covalent inhibitors was
assessed as described in Singh et al. (2011). The potency and
selectivity of a covalent inhibitor are governed by two parameters,
namely, K i, the dissociation constant of the initial non-covalent
complex, and k2, the rate of the subsequent covalent bond-










E and I denote a protein target and its covalent inhibitor,
respectively. E · I is the initial non-covalent complex, and E –
I is the final covalent complex. To obtain the K i and k2 rates,
the fluorescence polarization signal after inhibitor treatment was
plotted against the incubation time and fit using a one-phase
decay function to obtain the observed rate constant, kobs. This
was repeated for several inhibitor concentrations. Then, kobs was
plotted against the concentration of the inhibitor, and the data
were fit to a hyperbolic equation kobs = k2 × [I]Ki + [I] to obtain K i and
k2. The ratio of k2/K i represents the second-order rate constant
of the reaction of the covalent inhibitor with the target.
Composite Drug Activity Score
The composite drug activity score was obtained by computing the
activity of the compounds across various assays performed. The
desired properties taken into consideration are a high activity in
the spheroid assay, a higher selectivity for MDA-MB-231 over Hs
578T in the spheroid assay, a lower toxicity in the 2D assay against
Hs 578T as compared to MDA-MB-231 cells, and a higher affinity
to CaM. The final score is obtained using the equation below:










BRET assays were essentially performed as described by others
(Lavoie et al., 2013; Bery et al., 2018). About 100,00–150,000
HEK293-EBNA (Meissner et al., 2001) cells were seeded per
well of a 12-well plate in 1 ml of DMEM containing 10%
FBS and 2 mM L-glutamine and were grown for 24 h. Next
day, Rluc8-tagged donor and GFP2-tagged acceptor constructs
were transfected into cells using a jetPRIME transfection reagent
(cat. no. 114-75, Polyplus). Each well was transfected with
about 1 µg of plasmid DNA using 3 µl of the jetPRIME
reagent. For BRET donor saturation titration experiments, the
concentration of donor plasmid (25 ng) was kept constant, and
the concentration of acceptor plasmid was increased from 0 to
500 ng for RasG12V BRET pairs and 0–1,000 ng for K-Ras/CaM
BRET pairs. The empty pcDNA3.1(-) plasmid was used to top-up
the total DNA load per transfection. After 24 h of transfection,
cells were treated with compounds or vehicle control (DMSO
0.2% v/v in a growth medium) at the specified concentration
for 24 h or the stipulated time period in case of the time-
course experiments. The cells from one well of a 12-well plate
were collected, washed, and re-plated in PBS (cat. no. 14190-
094, Gibco, Thermo Fisher Scientific) on flat bottom, white
96-well plates (cat. no. 236108, Nunc, Thermo Fisher Scientific)
as four technical replicates containing 90 µl of cell suspension
per well. Then fluorescence intensity followed by BRET readings
were carried out on a Clariostar (BMG Labtech) plate reader at
25◦C. The fluorescence intensity (RFU) of GFP2 was measured
with excitation at 405 ± 10 nm and emission 515 ± 10 nm; it
is proportional to the acceptor concentration [acceptor]. BRET
readings were taken well by well by adding 10 µl of 100 µM
coelenterazine 400a (cat. no. C-320, GoldBio), the Rluc8 substrate
to each well (final concentration of 10 µM) using the injector
present in the plate reader. Luminescence emission intensities
were simultaneously recorded at 410± 40 nm (RLU, proportional
to [donor]) and 515± 15 nm (BRET signal).
The raw BRET ratio was calculated as the BRET signal
measured at 515 nm divided by the emission signal measured at
410 nm (RLU). The BRET ratio was obtained by subtracting the
raw BRET ratio by a background BRET signal measured for cells
expressing only the donor (Bacart et al., 2008) as indicated in the
formula below:
BRET ratio =
λem 515 nm(donor + acceptor)
λem 410 nm(donor + acceptor)
−
λem 515 nm(donor only)
λem 410 nm(donor only)
with donor+acceptor denoting cells transfected with the BRET
pair and donor only being cells expressing only the donor.
The expression of the acceptor relative to the
donor ([acceptor]/[donor]) was determined as
relative expression = RFURLU .
For BRET donor saturation titration experiments, the
BRET ratio was plotted against the [acceptor]/[donor] ratio.
Technical repeat data points were averaged, and data points
from all biological repeats were collected into one graph for
subsequent fitting. The BRET ratio vs. relative expression data
were fitted using a binding saturation equation in the Prism
(GraphPad) software to obtain BRETmax and BRET50 using the
equation y = BRETmax × xBRET50 + x , where x is the relative expression and
y is the BRET ratio. BRETmax represents the maximum saturation
BRET signal and depends on the structural parameters (distance,
orientation) of the BRET complex. BRET50 corresponds to the
ratio of the acceptor construct over the donor construct required
to attain 50% of the maximum BRET signal and is a measure of
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the effective relative affinity between the interacting BRET pair
(Marullo and Bouvier, 2007).
When applying the DSS analysis to nanoclustering-BRET
data, we used mevastatin (10 µM) to obtain the asymptote
parameter (a) for the maximal inhibition effect, as it prevents the
prenylation of Ras proteins, their plasma membrane trafficking,
and therefore nanoclustering. Otherwise, normalized BRET ratio
data were converted to % inhibition and then subsequently
uploaded onto the Breeze site (see text footnote 1).
Using BRET donor saturation data, the A/D plasmid ratio at
which the BRET ratio changes most linearly with the relative
expression was determined for each BRET sensor and then used
for testing compound treatments.
ATARiS Gene Dependence Score
To generate the ATARiS sensitivity plots, Excel files
corresponding to the normalized viability data for the siRNA
knockdown of each gene of interest were downloaded from the
publicly available database of the project DRIVE2 (McDonald
et al., 2017). The Project DRIVE study is a large-scale RNAi
screen in which 2D viability effects of mRNA knockdown were
assessed (McDonald et al., 2017). The ATARiS algorithm was
used in this study to aggregate consistent shRNA activity to gene
level activity (Shao et al., 2013). From the Excel files of each gene
of interest, the sensitivity score data were extracted, and a double
gradient heatmap plot was generated using Prism (GraphPad).
Higher gene dependence (of 2D viability) is indicated by a
negative score, while scores zero or above represent no or
neutral effects.
Confocal Imaging
The localization of Ras and CaM fusion proteins was visualized
by confocal microscopy. For imaging, MDCK cells were
cultured in DMEM supplemented with 10% FBS and 2 mM
L-glutamine at 37 ◦C with 5% CO2. Cells were seeded on
glass coverslips 1.5H (cat. no. LH22.1, Carl Roth) in 6-well
plates (cat. no. 657160, Cellstar, Greiner Bio-One), and plasmids
were transiently transfected with jetPRIME. Cells were fixed
48 h after the transfection with 4% paraformaldehyde (cat. no.
43368, Alfa Aesar) in PBS for 10 min at ambient temperature.
After washing with PBS-Tween 0.05% (cat. no. 9127.1, Carl
Roth), DNA was stained with a 1 µg/ml solution of DAPI
(cat. no. D1306, Thermo Fisher Scientific) diluted in PBS for
10 min. The coverslips were mounted onto glass slides using
Vectashield (cat. no. H-1000, Vector Laboratories). Images were
captured on a spinning disk confocal microscope (Andor, Oxford
Instruments), fitted with a Zyla 5.5 sCMOS camera (Andor,
Oxford Instruments), using a plan APO 60 × /1.40 Ph3 DM
oil immersion objective (Nikon) and NIS-Elements Imaging
Software (Nikon).
To evaluate the effect of compounds on centrosome numbers
during mitosis, HeLa cells were seeded in 6-well plates onto sterile
coverslips and cotransfected with 0.5 µg of pmCherry-CaM
and 1.5 µg pEGFP-Centrin1 plasmids using 4 µl of jetPRIME.
Twenty-four hours after the transfection, cells were synchronized
2https://oncologynibr.shinyapps.io/drive/
with 60 ng/ml of nocodazole for 16 h. After the removal of
nocodazole, the cells were treated with the protease inhibitor
MG132 (10 µM) to block the cells in metaphase and either
calmidazolium (20 µM), 1 (50 µM), or DMSO (0.5%) for
2 h. Cells were then fixed with 4% paraformaldehyde in PBS
for 10 min at ambient temperature. After washing with PBS-
Tween 0.05%, DNA was stained with a 1 µg/ml solution of
DAPI diluted in PBS for 10 min. Coverslips were mounted on
glass slides using Vectashield, and images were captured on a
spinning disk confocal microscope. Images were analyzed with
the ImageJ software, and the number of transfected mitotic cells
with multipolar and normal bipolar phenotypes was counted
(between 35 and 70 cells per test condition). The percentage
multipolar vs. bipolar cells was computed to generate the plot
using the Prism software.
Data Analysis
All data analysis was performed using Prism (GraphPad) version
9 unless otherwise indicated. The number of independent
biological repeats, n, for each data set is provided in the relevant
figure legend. Unless otherwise stated, statistical significance was
evaluated using one-way ANOVA. A p-value< 0.05 is considered
statistically significant, and the statistical significance levels are
annotated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
∗∗∗∗p< 0.0001, or ns = not significant.
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